phased变异支持的循环肿瘤DNA作为大B细胞淋巴瘤一线治疗后的预后生物标志物:DIRECT研究结果
DIRECT是一项前瞻性多中心研究,评估循环肿瘤DNA(ctDNA)在大B细胞淋巴瘤(LBCL)中的效用。研究开发了淋巴瘤定制、开源的ctDNA检测流程,捕获每位患者数百个 phased变异(PV),并在一线治疗结束(EoT)时评估PV支持的微小残留病(MRD)的预后影响。结果显示,可检测到PV-MRD的患者2年TTP为42%,未检测到者为95%(P < .001;HR 13.7),且在接受全剂量蒽环类免疫化疗的患者中同样显著(45% vs 96%;P < .001;HR 15.4),优于传统影像学评估。
要点
- EoT PV-MRD可检测与不可检测者的2年TTP分别为42%与95%(HR 13.7,P < .001)。
- 全剂量蒽环类免疫化疗患者中2年TTP为45% vs 96%(HR 15.4),优于PET评估(HR 6.9)。
- PV-MRD检测的LoD95在患者间差异超过两个数量级,需报告患者特异性LoD95。
核心结论
- EoT PV-MRD可提供独立的预后信息,增强传统影像学评估之外的疗效评估。
- 研究支持将PV-MRD纳入临床试验和弥漫性LBCL的常规管理。
研究设计与样本
- DIRECT为前瞻性、多中心研究,评估ctDNA在LBCL患者中的效用。
- 开发了淋巴瘤定制、开源的ctDNA检测流程,捕获每位患者数百个PV。
- 采用landmark分析评估一线治疗结束(EoT)时PV支持的MRD的预后影响。
- EoT PV-MRD状态可获取的患者共155例,中位随访24.5个月。
主要发现
- 可检测与不可检测PV-MRD患者的2年TTP分别为42%与95%(P < .001;HR 13.7)。
- 全剂量蒽环类免疫化疗患者中,2年TTP分别为45%与96%(P < .001;HR 15.4)。
- PV-MRD优于传统影像学评估(PET的HR为6.9,PV-MRD的HR为16.9)。
- LoD95在患者间差异超过两个数量级,需报告患者特异性LoD95。
- 观察到无复发情况下持续PV-MRD,包括4例转化性滤泡性淋巴瘤中的3例。
关键数值与推荐
- EoT PV-MRD可检测与不可检测的2年TTP:42% vs 95%(P < .001;HR 13.7)。
- 全剂量蒽环类免疫化疗亚组2年TTP:45% vs 96%(P < .001;HR 15.4)。
- PET评估HR为6.9,PV-MRD的HR为16.9。
- LoD95患者间差异超过两个数量级。
临床怎么用
- EoT PV-MRD可用于LBCL一线治疗后的敏感且临床有意义的疗效评估。
- PV-MRD提供独立于传统影像学的预后信息,支持纳入临床试验和常规管理。
- 解读阳性PV-MRD时需注意无复发情况下持续阳性的可能,尤其转化性滤泡性淋巴瘤。
- 报告PV-MRD时应同时报告患者特异性LoD95。
局限性
- EoT PV-MRD状态可获取的患者为155例。
- 无复发情况下持续PV-MRD可能影响阳性结果的解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Circulating tumor DNA (ctDNA) is emerging as a promising tool to monitor treatment response in large B-cell lymphoma (LBCL). Tracking tumor-specific phased variants (PVs) allows ultrasensitive detection of minimal residual disease (MRD) that may enhance the accuracy of response assessment. Previous studies have been constrained by small cohort size, retrospective design, or assays limited to a single commercial provider. PATIENTS AND METHODS: DIRECT was a prospective, multisite study evaluating the utility of ctDNA in patients with LBCL. We developed a lymphoma-customized, open-source, ctDNA assay and pipeline that captured hundreds of PVs per patient. Using landmark analysis, we evaluated the prognostic impact of PV-supported MRD at the end of first-line therapy (EoT). RESULTS: EoT PV-MRD status was available for 155 patients. After a median of 24.5 months, 2-year time to tumor progression (TTP) for patients with detectable versus undetectable PV-MRD was 42% versus 95%, respectively (P < .001; hazard ratio [HR], 13.7). When restricted to patients receiving full-dose anthracycline-based immunochemotherapy, 2-year TTP was 45% versus 96%, respectively (P < .001; HR, 15.4), outperforming conventional radiological response assessment (HRs, 6.9 for positron emission tomography v 16.9 for PV-MRD). The limit of detection with 95% confidence (LoD95) varied by more than two orders of magnitude across patients, underscoring the need to report patient-specific LoD95. Persistent PV-MRD in the absence of relapse was noted, including three of four patients with transformed follicular lymphoma, highlighting a potential caveat when interpreting positive PV-MRD. CONCLUSION: EoT PV-MRD enables sensitive and clinically meaningful response assessment in LBCL. It provides independent prognostic information, enhancing EoT response assessment beyond conventional radiologic assessment. Our findings support the incorporation of PV-MRD into clinical trials and routine management of diffuse LBCL.
引用
- Krupka JA, Moutsopoulos I, Cutmore NH, et al. Phased Variant-Supported Circulating Tumor DNA as a Prognostic Biomarker After First-Line Treatment in Large B-Cell Lymphoma: Findings From the DIRECT Study. J Clin Oncol. 2025. PMID: 41428995. doi:10.1200/JCO-25-01587
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。